PYRUKYND Trademark
Trademark Overview
On Monday, December 9, 2024, a trademark application was filed for PYRUKYND with the United States Patent and Trademark Office. The USPTO has given the PYRUKYND trademark a serial number of 98892062. The federal status of this trademark filing is NEW APPLICATION - RECORD INITIALIZED NOT ASSIGNED TO EXAMINER as of Monday, December 9, 2024. This trademark is owned by Agios Pharmaceuticals, Inc.. The PYRUKYND trademark is filed in the Pharmaceutical Products category with the following description:
Pharmaceutical preparations, namely, for the activation of PKR (pyruvate kinase R), for the activation of PKM2 (pyruvate kinase isozyme M2), and for the prevention and treatment of blood disorders, sickle cell disease, pyruvate kinase deficiency (PKD), beta thalassemia and alpha thalassemia, genetically defined diseases affecting red blood cells, hereditary spherocytosis, hereditary elliptocytosis, dyserythropoiesis, hemolytic anemia, and other anemias
General Information
| Serial Number | 98892062 |
| Word Mark | PYRUKYND |
| Filing Date | Monday, December 9, 2024 |
| Status | 630 - NEW APPLICATION - RECORD INITIALIZED NOT ASSIGNED TO EXAMINER |
| Status Date | Monday, December 9, 2024 |
| Registration Number | 0000000 |
| Registration Date | NOT AVAILABLE |
| Mark Drawing | 0 - NOT AVAILABLE |
| Published for Opposition Date | NOT AVAILABLE |
Trademark Statements
| Description of Mark | The mark consists of four check mark designs joined at their bottoms, forming a stylized starburst shape with two purple triangles in the center; the check mark designs are colored turquoise, chartreuse, fuchsia and white, moving clockwise from the upper right of the design. The word "PYRUKYND" appears in stylized white lettering to the lower right of the starburst design, with the entire mark appearing upon a purple background. |
| Goods and Services | Pharmaceutical preparations, namely, for the activation of PKR (pyruvate kinase R), for the activation of PKM2 (pyruvate kinase isozyme M2), and for the prevention and treatment of blood disorders, sickle cell disease, pyruvate kinase deficiency (PKD), beta thalassemia and alpha thalassemia, genetically defined diseases affecting red blood cells, hereditary spherocytosis, hereditary elliptocytosis, dyserythropoiesis, hemolytic anemia, and other anemias |
| Indication of Colors claimed | The color(s) purple, fuchsia, chartreuse, turquoise and white is/are claimed as a feature of the mark. |
Classification Information
| International Class | 005 - Pharmaceutical and veterinary preparations; sanitary preparations for medical purposes; dietetic substances adapted for medical use, food for babies; plasters, materials for dressings; material for stopping teeth, dental wax; disinfectants; preparations for destroying vermin; fungicides, herbicides. |
| US Class Codes | 005, 006, 018, 044, 046, 051, 052 |
| Class Status Code | 6 - Active |
| Class Status Date | Monday, December 9, 2024 |
| Primary Code | 005 |
| First Use Anywhere Date | NOT AVAILABLE |
| First Use In Commerce Date | NOT AVAILABLE |
Trademark Owner History
| Party Name | Agios Pharmaceuticals, Inc. |
| Party Type | 10 - Original Applicant |
| Legal Entity Type | 03 - Corporation |
| Address | Cambridge, MA 02139 |
Trademark Events
| Event Date | Event Description |
| Monday, December 9, 2024 | NEW APPLICATION ENTERED |
| Monday, December 9, 2024 | APPLICATION FILING RECEIPT MAILED |
